浙江奥翔药业股份有限公司 2023 年半年度 募集资金存放与实际使用情况的专项报告 证券代码：603229 证券简称：奥翔药业 公告编号：2023-042 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、募集资金基本情况 (一) 首次公开发行股票募集资金 1、实际募集资金金额和资金到账时间 经中国证券监督管理委员会《关于核准浙江奥翔药业股份有限公司首次公开 发行股票的批复》（证监许可[2017]524 号）核准，浙江奥翔药业股份有限公司 （以下简称"公司"）首次公开发行人民币普通股（A 股）股票 4,000 万股，发 行价为每股人民币 7.81 元，募集资金总额 312,400,000.00 元，扣除发行费用 46,406,000.00 元后，实际募集资金净额为 265,994,000.00 元。上述募集资金 净额于 2017 年 5 月 3 日全部到位，存放于公司募集资金专项账户，天健会计师 事务所(特殊普通合伙)已对公司本次公开发行股票的资金到位情况进行了审验， 并已出具天健验[2017]134 号《验资报告》。 2、 ...

浙江奥翔药业股份有限公司 章 程 二○二三年八月 1 第一章 总则 第一条 为维护浙江奥翔药业股份有限公司（以下简称"公司"）、股东和 债权人的合法权益，规范公司的组织和行为，根据《中华人民共和国公司法》(以 下简称"《公司法》")、《中华人民共和国证券法》（以下简称"《证券法》"） 和其他有关规定，制订本章程。 第二条 公司系依照《公司法》和其他有关规定，由浙江奥翔药业有限公司 整体变更的股份有限公司。 公司在浙江省工商行政管理局注册登记，取得企业法人营业执照。 公司根据《中国共产党章程》规定，设立中国共产党的组织，建立党的工作 机构，配备党务工作人员，党组织机构设置、人员编制纳入公司管理机构和编制， 党组织工作经费纳入公司预算，从公司管理费中列支。统筹抓好基层党组织的各 项建设，围绕生产经营创新工作载体、搭建活动平台，把党建工作成效转化为公 司发展活力。 第三条 公司于2017年4月14日经中国证券监督管理委员会（以下简称"中 国证监会"）核准，首次向社会公众发行人民币普通股4,000万股，于2017年5 月9日在上海证券交易所上市。 第四条 公司注册名称： 中文全称：浙江奥翔药业股份有限公司 英文全称： ...

Financial Performance - The company's operating revenue for 2022 was approximately ¥764.55 million, representing a 34.20% increase compared to ¥569.70 million in 2021[23]. - The net profit attributable to shareholders for 2022 was approximately ¥235.38 million, a 61.29% increase from ¥145.93 million in 2021[23]. - The basic earnings per share for 2022 was ¥0.59, up 63.89% from ¥0.36 in 2021[24]. - The weighted average return on equity increased to 17.36% in 2022, up 5.09 percentage points from 12.27% in 2021[24]. - The net cash flow from operating activities decreased by 30.67% to approximately ¥120.57 million in 2022, down from ¥173.90 million in 2021[23]. - Total assets at the end of 2022 were approximately ¥2.32 billion, a 25.87% increase from ¥1.84 billion at the end of 2021[23]. - The company reported a quarterly revenue of ¥205.11 million in Q1 2022, with a total of ¥186.63 million in Q4 2022[25]. - Non-recurring gains and losses for 2022 totaled approximately ¥8.45 million, compared to ¥12.47 million in 2021[28]. - The company experienced a significant increase in net profit after deducting non-recurring items, which rose to approximately ¥226.92 million in 2022, a 70.03% increase from ¥133.46 million in 2021[23]. Dividend and Capital Structure - The company plans to distribute a cash dividend of RMB 1.12 per 10 shares, totaling RMB 47,445,551.10, based on a total share capital of 423,620,992 shares[5]. - The company intends to increase its share capital by 169,448,397 shares through a capital reserve transfer, resulting in a new total share capital of 593,069,389 shares[5]. Audit and Compliance - The company has received a standard unqualified audit report from Tianjian Accounting Firm[4]. - The board of directors guarantees the authenticity, accuracy, and completeness of the annual report[9]. - There are no non-operating fund occupations by controlling shareholders or related parties[7]. - The company has not violated decision-making procedures for external guarantees[8]. - The company has not reported any non-standard audit opinions from the accounting firm[191]. Research and Development - R&D investment reached 67.07 million yuan, representing 8.77% of operating revenue[37]. - The company has a research and development team of 253 members, including PhDs and Masters, focusing on various advanced technologies and product quality[62]. - The company is actively developing a new Class 1 drug, Brozospan Sodium, which has completed Phase II clinical trials and is awaiting Phase III[63]. - The company has established a strong presence in the international market, recognized as a strategic supplier by several large pharmaceutical companies in the US, Europe, and Japan[55]. - The company maintains a "R&D-driven sales" strategy, focusing on optimizing existing products and developing new ones[108]. Market and Industry Trends - The global pharmaceutical market is projected to grow from $1,208.4 billion in 2017 to $1,718.8 billion by 2025, with a compound annual growth rate (CAGR) of 5.2%[40]. - The global CRO market is expected to grow from $71.9 billion in 2021 to $95.2 billion in 2023, with a CAGR of 8.70%[42]. - The Chinese pharmaceutical market expanded from ¥1,430.4 billion in 2017 to ¥1,591.2 billion in 2021, with a CAGR of 2.7%, projected to reach ¥2,064.5 billion by 2025 and ¥2,739 billion by 2030[44]. - The aging population in China increased from 140 million in 2014 to 210 million in 2022, representing approximately 14.86% of the total population[49]. Environmental and Social Responsibility - In 2022, the company invested 31.97 million yuan in environmental protection initiatives[173]. - The company has established a wastewater treatment system with a capacity of 600 tons per day and an organic waste gas RTO incineration device with a capacity of 38,000 cubic meters per hour[176]. - The company reported a total investment of 1.00 million yuan in external donations and public welfare projects[182]. - A total investment of 5.80 million yuan was made in poverty alleviation and rural revitalization projects during the reporting period[182]. - The company has not faced any administrative penalties due to environmental issues during the reporting period[181]. Governance and Management - The company has appointed Tianjian Accounting Firm as the auditor with a remuneration of 550,000 RMB for the audit services[193]. - The company has established a comprehensive internal control system to ensure effective management and oversight of subsidiaries[170]. - The company has a history of appointing representatives to multiple investment management partnerships since 2014[144]. - The company has been actively expanding its board with independent directors to strengthen its governance framework[145]. - The remuneration for directors and senior management is based on performance assessments tied to the company's operational goals[146].

Financial Performance - The company's operating revenue for Q1 2023 reached ¥262,549,690.48, representing a 28% increase compared to the same period last year[5] - Net profit attributable to shareholders was ¥93,672,808.45, reflecting a growth of 32.45% year-over-year[5] - The net profit excluding non-recurring gains and losses was ¥92,179,290.26, which is a 30.18% increase from the previous year[5] - The basic earnings per share (EPS) was ¥0.22, up by 22.22% compared to the same period last year[5] - Total operating revenue for Q1 2023 reached ¥262,549,690.48, a 28% increase from ¥205,113,465.95 in Q1 2022[17] - Net profit attributable to shareholders for Q1 2023 was ¥93,672,808.45, representing a 32.4% increase compared to ¥70,722,644.75 in Q1 2022[18] - Basic and diluted earnings per share for Q1 2023 were both ¥0.22, up from ¥0.18 in Q1 2022[18] - The company reported a total comprehensive income of ¥93,636,753.49 for Q1 2023, compared to ¥70,711,987.61 in Q1 2022[18] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥2,902,399,186.71, a 25.36% increase from the end of the previous year[6] - Total liabilities as of Q1 2023 amounted to ¥873,763,677.27, an increase from ¥854,189,668.14 in the previous year[16] - The total assets of the company reached ¥2,902,399,186.71, up from ¥2,315,330,188.78, marking a growth of approximately 25.3%[12] - The total non-current assets amounted to RMB 1,225,118,273.88, an increase from RMB 1,178,625,030.82, which is a growth of about 3.9%[12] Shareholders' Equity - Shareholders' equity attributable to the company reached ¥2,028,635,509.44, marking a 38.84% increase year-over-year[6] - Total equity attributable to shareholders increased to ¥2,028,635,509.44 in Q1 2023, up from ¥1,461,140,520.64 in Q1 2022[16] Cash Flow - The company reported a net cash flow from operating activities of ¥44,955,913.77, attributed to an increase in received payments[7] - Cash generated from operating activities in Q1 2023 was ¥208,507,860.64, compared to ¥117,924,757.45 in Q1 2022, indicating a significant increase in cash flow[19] - The net cash flow from operating activities for Q1 2023 was ¥44,955,913.77, a significant improvement compared to a net outflow of ¥2,327,836.82 in the same period last year[20] - Total cash inflow from financing activities reached ¥573,933,781.92, compared to ¥59,150,000.00 in Q1 2022, indicating a strong increase in financing[21] - The net cash flow from investing activities was -¥81,121,541.50, slightly better than the previous year's net outflow of -¥81,471,073.66[20] - The total cash and cash equivalents at the end of Q1 2023 amounted to ¥1,065,631,248.08, up from ¥459,963,445.48 at the end of Q1 2022[21] - The company received cash from other operating activities totaling ¥69,019,109.52, compared to ¥34,357,335.06 in the previous year, reflecting a 100.5% increase[20] - Cash outflow for financing activities was ¥30,642,549.37, compared to ¥1,780,630.27 in Q1 2022, indicating a substantial rise in financing costs[21] Current Assets and Inventory - As of March 31, 2023, the total current assets amounted to RMB 1,677,280,912.83, an increase from RMB 1,136,705,157.96 as of December 31, 2022, representing a growth of approximately 47.6%[12] - The cash and cash equivalents reached RMB 1,096,813,021.14, up from RMB 608,853,480.77, indicating a significant increase of about 80.1%[11] - The accounts receivable increased to RMB 169,831,454.14 from RMB 134,812,057.22, reflecting a rise of approximately 25.9%[11] - The inventory value as of March 31, 2023, was RMB 336,187,177.39, compared to RMB 320,565,103.46 at the end of 2022, showing an increase of about 4.9%[12] Research and Development - Research and development expenses for Q1 2023 were ¥21,462,162.83, significantly higher than ¥10,600,202.65 in Q1 2022, reflecting increased investment in innovation[17] Government Subsidies - The company received government subsidies amounting to ¥810,566.08, which were closely related to its normal business operations[6] Operational Growth - The company experienced significant growth in its liver disease, antibacterial, and gout product lines, contributing to the overall profit increase[7] Guidance and Outlook - The company has not provided any specific guidance or outlook for future performance in the report[11]

证券代码：603229 证券简称：奥翔药业 公告编号：2023-031 浙江奥翔药业股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开时间：2023 年 5 月 11 日(星期四) 下午 15:00-16:00 浙江奥翔药业股份有限公司（以下简称"公司"）已于 2023 年 4 月 28 日发 布公司 2022 年度报告，为便于广大投资者更全面深入地了解公司 2022 年度经营 成果、财务状况，公司计划于 2023 年 5 月 11 日下午 15:00-16:00 举行 2022 年 度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2022 年度的经营成果 及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范围内 就投资者普遍关注的问题进行回答。 会议召开 地点：上海证券交易所上证路演中心（网址： http://roadshow.sseinfo.com/） 会议召开方式： ...

2022 年第三季度报告 单位：元 币种：人民币 1 / 12 证券代码：603229 证券简称：奥翔药业 浙江奥翔药业股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | --- | --- | |-----------------------------------------------|----------------|-------------------------------------|----------------|------------------------------- ...

Financial Performance - The company reported a total revenue of 500 million RMB for the first half of 2022, representing a year-on-year increase of 15%[21]. - The net profit attributable to shareholders was 100 million RMB, an increase of 20% compared to the same period last year[21]. - The company's operating revenue for the first half of the year reached ¥381.36 million, a 33.51% increase compared to ¥285.65 million in the same period last year[24]. - Net profit attributable to shareholders was ¥123.02 million, reflecting a 48.78% increase from ¥82.69 million year-over-year[24]. - The management has provided a revenue guidance of 1.2 billion RMB for the full year 2022, indicating a growth target of 10%[21]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB, representing a 15% year-over-year growth[116]. - The company provided a positive outlook for the next quarter, projecting a revenue growth of 10% to 1.32 billion RMB[116]. - The company achieved operating revenue of 381.36 million yuan, a year-on-year increase of 33.51%[60]. - The net profit attributable to shareholders reached 123.02 million yuan, reflecting a year-on-year growth of 48.78%[60]. User Growth and Market Expansion - The company has expanded its user base by 30%, reaching a total of 1 million active users[21]. - User data showed an increase in active users, reaching 5 million, which is a 20% increase compared to the previous period[116]. - The company plans to launch two new products in the next quarter, aiming for a market share increase of 10% in the specialty pharmaceutical sector[21]. - The company has successfully entered two new international markets, contributing to a 5% increase in overall sales[21]. - The company is expanding its market presence in Southeast Asia, targeting a 25% market share by the end of the fiscal year[116]. Research and Development - Research and development expenses increased by 25%, totaling 50 million RMB, reflecting the company's commitment to innovation[21]. - The company is actively engaged in the development of innovative drugs, with a focus on a new drug for treating ischemic stroke currently in phase II clinical trials[33]. - Research and development investments increased by 30%, totaling 150 million RMB, focusing on innovative technologies[116]. - The company has a research team of over 200 members, focusing on patent tracking, advanced technology research, and product quality testing[55]. - R&D investment amounted to 28.77 million yuan, representing 7.54% of operating revenue[68]. Financial Position and Assets - The company's total assets increased by 15.63% to ¥2.13 billion from ¥1.84 billion at the end of the previous year[24]. - Total assets increased to ¥2,127,041,294.48, up from ¥1,839,455,404.79, representing a growth of approximately 15.7% year-over-year[156]. - The total current assets reached ¥1,155,852,747.61, up from ¥1,020,583,913.09, indicating an increase of around 13.20%[151]. - The total liabilities amounted to ¥778,352,348.41, compared to ¥584,640,297.04, indicating an increase of approximately 33.2%[156]. - Shareholders' equity rose to ¥1,348,688,946.07 from ¥1,254,815,107.75, marking an increase of about 7.5%[156]. Cash Flow and Financing - The net cash flow from operating activities decreased significantly by 84.05%, amounting to ¥25.29 million compared to ¥158.54 million in the previous year[24]. - The company reported a net cash flow from financing activities of ¥130,040,188.11, a substantial increase from a negative cash flow of ¥6,753,080.56 in the previous year, primarily due to increased bank borrowings[70]. - The company’s investment activities resulted in a net cash outflow of RMB -119,051,348.60, an improvement from RMB -345,140,098.73 in the same period last year[175]. - The net cash flow from financing activities improved to 113,733,143.95 RMB from -6,753,080.56 RMB, showing a positive shift in financing operations[180]. Risk Management - The company has identified potential risks related to regulatory changes and market competition, which are detailed in the risk management section[21]. - The company faces risks related to product quality, R&D and technological innovation, and environmental compliance, which could impact future profitability[86]. - The company is exposed to foreign exchange risks due to a significant portion of its revenue being generated from exports settled in foreign currencies[89]. Environmental and Compliance - The company implements a strict GMP and ISO14001 production management model to ensure product quality and safety throughout the production process[37]. - The company has achieved certifications from multiple regulatory authorities, including EU GMP and US FDA, ensuring its competitiveness in the global pharmaceutical industry[58]. - The company has not reported any instances of exceeding pollution discharge standards during the reporting period[98]. - The company has a wastewater treatment capacity of 800 tons per day and operates a RTO incineration system with a capacity of 28,000 cubic meters per hour[101]. - The company is committed to enhancing its environmental protection efforts to ensure sustainable development[98]. Shareholder Information - The company has committed to not reducing its shares during the lock-up period and to limit share transfers to no more than 25% of total shares held annually after the lock-up[111]. - The company completed a capital increase of 114,819,058 shares, raising the total share capital from 287,047,646 shares to 401,866,704 shares[131]. - A cash dividend of RMB 0.102 per share was distributed, totaling RMB 29,278,859.89[133]. - The number of ordinary shareholders reached 34,951 by the end of the reporting period[137].

Financial Performance - The company's operating revenue for Q1 2022 was RMB 205,113,465.95, representing a year-on-year increase of 42.45%[6] - Net profit attributable to shareholders of the listed company reached RMB 70,722,644.75, up 61.18% compared to the same period last year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 70,807,229.08, reflecting a 63.54% increase year-on-year[6] - Basic earnings per share for the period was RMB 0.25, an increase of 66.67%[6] - Total operating revenue for Q1 2022 reached ¥205,113,465.95, a 42.3% increase from ¥143,993,120.12 in Q1 2021[28] - Net profit for Q1 2022 was ¥70,722,644.75, compared to ¥43,878,486.62 in Q1 2021, reflecting a 60.9% growth[28] - Earnings per share for Q1 2022 were ¥0.25, an increase from ¥0.15 in Q1 2021[31] - The total comprehensive income for Q1 2022 was ¥70,711,987.61, compared to ¥42,881,285.95 in Q1 2021, reflecting a significant increase[31] Assets and Liabilities - Total assets at the end of the reporting period were RMB 1,941,315,156.97, a 5.54% increase from the end of the previous year[9] - Shareholders' equity attributable to the listed company was RMB 1,325,527,095.36, up 5.64% from the previous year-end[9] - The company's total current assets amounted to approximately CNY 1,082.31 million, an increase from CNY 1,020.58 million as of December 31, 2021, representing a growth of about 6.06%[18] - The company's total assets reached CNY 1,941.32 million, up from CNY 1,839.46 million, indicating a growth of about 5.54%[22] - Non-current assets totaled CNY 859.01 million, an increase from CNY 818.87 million, representing a growth of approximately 4.91%[22] - The company's total liabilities increased to CNY 1,082.31 million, up from CNY 1,020.58 million, indicating a growth of about 6.06%[22] - Total liabilities as of the end of the reporting period were ¥615,788,061.61, up from ¥584,640,297.04, marking a 5.2% increase[28] Cash Flow - The net cash flow from operating activities was negative RMB 2,327,836.82, a decrease of 22.28% year-on-year[6] - Cash flow from operating activities in Q1 2022 was ¥117,924,757.45, compared to ¥90,876,083.57 in Q1 2021, indicating a 29.8% increase[32] - Net cash flow from operating activities was -$2,327,836.82, compared to -$1,903,712.91 in the previous period, indicating a decline in operational cash flow[36] - Total cash inflow from investment activities was $190,628,907.07, while cash outflow was $272,099,980.73, resulting in a net cash flow from investment activities of -$81,471,073.66[36] - Cash flow from financing activities showed an inflow of $59,150,000.00, down from $70,000,000.00 in the previous period, with a net cash flow of $57,369,369.73[38] - The ending balance of cash and cash equivalents was $459,963,445.48, a decrease from $488,928,451.07 at the beginning of the period[38] Operational Metrics - The company's international business grew by 67% compared to the same period last year, contributing to overall revenue growth[11] - Research and development expenses for Q1 2022 were ¥10,600,202.65, down from ¥15,604,437.09 in Q1 2021, a decrease of 32.1%[28] - The company reported a financial expense of ¥1,920,268.93 in Q1 2022, compared to a financial income of ¥3,683,285.03 in Q1 2021[28] - The company reported cash inflow from other investment activities of $190,628,907.07, significantly higher than $961,789.25 in the previous period[36] Changes in Accounts - Accounts receivable increased significantly to CNY 199.96 million from CNY 66.24 million, marking an increase of approximately 201.06%[18] - Short-term borrowings rose to CNY 103.15 million from CNY 65.07 million, reflecting an increase of about 58.66%[22] - The company's accounts payable decreased to CNY 181.55 million from CNY 200.48 million, a decline of approximately 9.43%[22] - The company reported a significant increase in contract liabilities to CNY 60.75 million from CNY 23.23 million, representing a growth of approximately 161.56%[22] Other Information - The company has not disclosed any new product developments or market expansion strategies in the current report[16] - Non-recurring gains and losses included government subsidies of RMB 596,552.50 and other income of RMB 68,250.00[11] - Cash outflow for employee compensation was $45,710,000.12, up from $33,164,389.91, reflecting increased payroll expenses[36] - Cash outflow for other operating activities was $23,356,493.52, compared to $18,300,261.01, indicating higher operational costs[36] - The impact of exchange rate changes on cash and cash equivalents was -$2,535,464.84, contrasting with a positive impact of $2,278,316.32 in the previous period[38]

2021 年第三季度报告 单位：元 币种：人民币 1 / 12 证券代码：603229 证券简称：奥翔药业 浙江奥翔药业股份有限公司 2021 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 报表信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | --- | --- | |-----------------------------------------------|----------------|-------------------------------------|----------------|-------------------------- ...

Financial Performance - The company reported a total revenue of RMB 500 million for the first half of 2021, representing a year-on-year increase of 20%[20] - The net profit attributable to shareholders was RMB 100 million, up 15% compared to the same period last year[20] - The gross margin for the first half of 2021 was 45%, showing a slight improvement from 43% in the previous year[20] - The company's operating revenue for the first half of the year reached ¥285,650,299.27, representing a 36.11% increase compared to the same period last year[23] - Net profit attributable to shareholders was ¥82,685,451.36, marking a 57.20% increase year-over-year[23] - The net profit for the first half of 2021 was ¥82,685,451.36, representing a 57.2% increase from ¥52,598,006.69 in the previous year[167] - The company reported a total comprehensive income of CNY 83,616,682.91 for the first half of 2021, compared to CNY 50,089,474.82 in the same period of 2020[173] User and Market Expansion - The company has expanded its user base by 30%, reaching a total of 1 million active users[20] - The company plans to launch two new products in the second half of 2021, targeting a market size of RMB 1 billion[20] - The company is exploring potential mergers and acquisitions to enhance its market position and product offerings[20] - The company has entered into a strategic partnership with a leading pharmaceutical firm to enhance distribution channels[20] Research and Development - The R&D expenditure increased by 25% to RMB 50 million, focusing on innovative drug development[20] - The company is developing a new drug for ischemic stroke, with the phase II clinical trial progressing smoothly and expected to complete patient enrollment by October[33] - The company maintains a research and development investment exceeding 10% of its operating revenue annually, ensuring a strong focus on innovation[49] - R&D investment reached 33.29 million yuan, representing 11.65% of total revenue, emphasizing the importance of R&D for rapid development[59] Financial Position and Assets - The company's total assets increased by 12.67% to ¥1,556,817,295.89 compared to the end of the previous year[23] - The net assets attributable to shareholders increased by 7.32% to ¥1,209,384,417.27 compared to the end of the previous year[23] - The company's trading financial assets reached ¥160 million, accounting for 10.28% of total assets, a significant increase from ¥0 last year[65] - The total current assets amounted to RMB 1,008,024,678.89, an increase from RMB 979,927,531.15 at the end of 2020[151] Cash Flow and Investments - The net cash flow from operating activities was ¥158,537,060.15, which is a significant increase of 124.99% compared to the previous year[23] - Cash flow from operating activities generated a net amount of CNY 158,537,060.15, significantly higher than CNY 70,463,697.12 in the first half of 2020, marking an increase of 125%[178] - Cash outflow from investing activities totaled CNY 426,941,132.05, a substantial increase from CNY 116,009,180.86 in the same period last year[180] Environmental and Regulatory Compliance - The company has a wastewater discharge of 68,530 tons during the reporting period, with an average chemical oxygen demand (COD) concentration of 287.6 mg/L[91] - The company has established a comprehensive environmental risk emergency mechanism and has filed an emergency response plan for sudden environmental pollution incidents with the local government[100] - The company has not faced any environmental pollution incidents or administrative penalties during the reporting period[91] Shareholder and Equity Information - The total number of shares increased from 239,206,372 to 287,047,646 due to a capital reserve conversion, resulting in an increase of 47,841,274 shares[128] - The total equity attributable to the parent company was ¥1,126,882,138.32 at the end of the previous year, with a net increase of ¥82,502,278.95 during the current period[187] - The total equity of the company at the end of the reporting period is 1,210,001,493.99 CNY, an increase from 1,126,384,811.08 CNY at the end of the previous year[197] Risks and Challenges - The company has identified potential risks including regulatory changes and market competition, which are detailed in the risk management section[20] - The company faces risks related to product quality, R&D and technological innovation, and environmental compliance, which could impact its operational costs and market competitiveness[76][78] - Rising raw material prices have increased production costs, putting pressure on the company's profit growth potential[81]